Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEACH: Toll-like receptor 9 enhancement of antiviral immunity in chronic HIV-1 infection
2014-005634-59Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Apr 2015
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lefitolimod in human immunodeficiency virus infection (HIV), sponsored by Aarhus University Hospital. Primary endpoint: Part A: Changes in proportions of activated NK cells. Started Apr 2015; status: completed.
02
Drugs
lefitolimod
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2014-005634-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005634-59.